Economic impact of pharmacists' interventions with nonsteroidal antiinflammatory drugs

Annals of Pharmacotherapy

Volumn 37, Issue 3, 2003, Pages 332-338

  Guignard, Adrienne P ^a,b,d   Couray Targe, Sandrine ^a   Colin, Cyrille ^a   Chamba, Geneviève ^c   Monsanto, Homero A ^e  

^a HOSPICES CIVILS DE LYON   (France)

^b LOUIS PRADEL HOSPITAL   (France)

^c UNIVERSITÉ LYON 1   (France)

^d Service Pharmaceutique   (France)

^e NONE

Author keywords

Adverse events; Community pharmacy; Nonsteroidal antiinflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZAPROPAZONE; DICLOFENAC; DIFLUNISAL; FENOPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC; TENOXICAM;

ABDOMINAL PAIN; ARTICLE; CONSTIPATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG SCREENING; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MEDICAL LITERATURE; MEDICAL RECORD; PATIENT CARE; PEPTIC ULCER; PHARMACIST; PHARMACY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; RISK ASSESSMENT; SELF MEDICATION; SIMULATION; VERTIGO; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; COMMUNITY PHARMACY SERVICES; COST SAVINGS; DECISION SUPPORT TECHNIQUES; GASTROINTESTINAL DISEASES; HUMANS; MODELS, ECONOMIC; PHARMACISTS; PROBABILITY; PROFESSIONAL ROLE; RISK MANAGEMENT; SELF MEDICATION; SENSITIVITY AND SPECIFICITY;

EID: 0037369472     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Ogle BG, McLean WM, Poston G. The clinical pharmacy services study. A study of clinical services provided by pharmacy hospitals. Can J Hosp Pharm 1996;49(suppl):S5-S21.
2. Hanlon JT, Weinberger M, Samsa GP, Schmader KE, Uttech KM, Lewis IK. et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med 1996;100:428-37.
3. Hatoum HT, Hutchinson RA, Witte KW, Newby GP. Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm 1988;22:252-9.
4. Rupp MT. Value of community pharmacists' interventions to correct prescribing errors. Ann Pharmacother 1992;26:1580-4.
5. Torok N, Brown G. The economic impact of clinical pharmacists' unsolicited recommendations. Hosp Pharm 1992;27:1052-3.1056-8,1060.
6. Mason JD, Colley CA. Effectiveness of an ambulatory care clinical pharmacist: a controlled trial. Ann Pharmacother 1993;27:555-9.
7. Strong DK, Tsang GWY. Focus and impact of pharmacists' interventions. Can J Hosp Pharm 1993;46:101-8.
8. Mutnick AH, Sterba KJ, Peroutka JA, Sloan NE, Beltz EA, Sorenson MK. Cost savings and avoidance from clinical interventions. Am J Health Syst Pharm 1997;54:392-6.
9. Suseno M, Tedeski L, Kent S, Rough S. Impact of documented pharmacists' interventions on patient care and cost. Hosp Pharm 1998;33:676-81.
10. Zermansky AG, Petty DR, Raynor DK, Freemantle N, Vail A, Lowe CJ. Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice. BMJ 2001;323:1340-3.
11. Raskin JB. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999;106(5B):3S-12S.
12. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998;104(3A):23S-9S.
13. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989;96:647-55.
14. Langman MJS. Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden? Pharmacoepidemiol Drug Saf 2001;10:13-9.
15. García Rodríguez LA, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-6.
16. Agrawal NM, Dajani EZ. Drug-induced ulcerogenesis. In: Friedman G, Jacobson ED, McCallum RW, eds. Gastrointestinal pharmacology and therapeutics. Philadelphia: Lippincott Raven, 1997:55-63.
17. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000;119:521-35.
18. Meckstroth S, Schwartz M, Agrawal N. NSAIDs. Safety implications of over-the-counter availability. Drug Saf 1992;7:241-4.
19. Coste J, Hanotin C, Leutnegger E. [Prescription of non-steroidal anti-inflammatory agents and risk of iatrogenic adverse effects: a survey of 1072 French general practitioners] French. Therapie 1995;50:265-70.
20. Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ, Goldstein JL. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics 2001;19(suppl 1):33-47.
21. Zabinski RA, Burke TA, Johnson J, Lavoie F, Fitzsimon C, Tratiak R, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001;19(suppl 1):49-58.
22. Chancellor JV, Hunsche E, de Cruz E, Sarasin FP. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics 2001;19(suppl 1):59-75.
23. Carrin GJ, Torfs KE. Economic evaluation of prophylactic treatment with Misoprostol in osteoarthritic patients treated with NSAIDs. The case of Belgium. Rev Epidemiol Sante Publique 1990;38:187-99.
24. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
25. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
26. Gutthann SP, García Rodríguez LA, Raiford DS. Individual nonsteroidal anfiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997;8:18-24.
27. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993;105:1078-88.
28. Hernández-Díaz S, García Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9.
29. McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am J Med 1998;150(5A):3S-9S.
30. Weil J, Langman MJS, Wainwright P, Lawson DH, Rawlins M, Logan RFA, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000;46:27-31.
31. Shorr RI, Wayne AR, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer events. Arch Intern Med 1993;153:1665-70.
32. Silverstein FE, Graham DY, Senior JR, Wyn Davies H, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
33. International classification of diseases. 9th rev. ed. Clinical modification. Washington, DC: Department of Health and Human Services, 1998.
34. Etude National des Coûts relatifs par GHM, année 99: Points ISA 99 (BO n°99/2 bis) et références des coûts [cited 2002 Jan 20]. Available from: URL: xlisar99.zip in www.lepmsi.fr/telechargeables/mco/index.html.
35. Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993;119:257-62.
36. Koch M, Dezi A, Ferrario F, Capurso L. Prevention of nonsteroidal antiinflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized clinical trials. Arch Intern Med 1996;156:2321-32.
37. Taha AS, Hudson N, Hawkey CJ, Swanell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. New Engl J Med 1996;334:1435-9.
38. Taha AS, Dahill S, Sturrock RD, Lee FD, Russell RI. Predicting NSAID related ulcers - assessment of clinical and pathological risk factors and importance of differences in NSAID. Gut 1994;35:891-5.
39. Gabriel SE, Jaakkimainen L, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993:36:447-59.
40. Kimmey MB. Role of endoscopy in nonsteroidal anti-inflammatory drug clinical trials. Am J Med 1998;105(A):28S-31S.
41. Hawkey CJ. Outcomes studies of drug induced ulcer complications: do we need them and how should they be done? BMJ 2000;321:291-3.
42. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. Facts and figures multiply, but do they add up? BMJ 1990;300:278-84.
43. Henry D, Lim LLY, García Rodríguez LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.
44. Champion GD, Hsii Feng P, Azuma T, Caughey DE, Ho Chan K, Kashiwasaki S, et al. NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus. Drugs 1997;53:6-19.
45. Florent C, Le Loët X, Bardin T. Facteurs de risque des accidents gastroduodénaux des AINS. Rev Rhum 1996 [Ed. Fr.];63:135-40.
46. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-96.
47. Phillips AC, Polisson RP, Simon LS. NSAIDs and the elderly. Toxicity and economic implications. Drugs Aging 1997;10:119-30.
48. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40.
49. De Pourvourville G. Preventing NSAID-induced gastrointestinal toxicity. Economic considerations, methodological problems and results. Pharmacoeconomics 1995;7:99-110.
50. Drummond MF, Bloom BS, Carrin G, Hillman AL, Hutchings HC, Knill-Jones RP, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care 1992;8:671-82.
51. Chevat C, Peña BM, Al MJ, Rutten FFH, with the Expert Panel on Resource Utilisation. Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective. Pharmacoeconomics 2001;19(suppl 1):17-32.
52. Herings RMC, Klungel OH. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in the Netherlands. Pharmacoeconomics 2001;19:655-65.
53. Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis. Ontario Ministry of Health Perspective. Pharmacoeconomics 2001;19:1039-49.
54. Peris F, Martínez E, Badia X, Brosa M. Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aclofenac and other NSAIDs. Pharmacoeconomics 2001;19:779-90.
55. Kröger E, Moisan J, Gregoire JP. Billing for cognitive services: understanding Québec pharmacists' behavior. Ann Pharmacother 2000;34:309-16.